Finch Therapeutics Group Inc logo

Finch Therapeutics Group Inc

$ 2.57 -0.03 (-1.15%) 10:08 PM EST
P/E:
At Loss
P/B:
0.63
Market Cap:
$ 122.56M
Enterprise V:
$ 74.56M
Volume:
21.70K
Avg Vol (2M):
82.46K
Volume:
21.70K
Market Cap $:
122.56M
PE Ratio:
At Loss
Avg Vol (2-Month):
82.46K
Enterprise Value $:
74.56M
PB Ratio:
0.63
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Finch Therapeutics Group Inc
NAICS : 325412 SIC : 2834
200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143
Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Name Current Vs Industry Vs History
Cash-To-Debt 1.9
Equity-to-Asset 0.7
Debt-to-Equity 0.35
Debt-to-EBITDA -0.78
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.75
Distress
Grey
Safe
Beneish M-Score -5.29
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 53.68
9-Day RSI 59.41
14-Day RSI 57.37
6-1 Month Momentum % -75.66
12-1 Month Momentum % -82.62

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.28
Quick Ratio 7.28
Cash Ratio 6.89
Days Sales Outstanding 31.12

Dividend & Buy Back

Name Current Vs Industry Vs History

Financials (Next Earnings Date:2022-11-10 Est.)

FNCH's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:FNCH

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 12.864
EPS (TTM) ($) -1.61
Beta 0
Volatility % 83.83
14-Day RSI 57.37
14-Day ATR ($) 0.222624
20-Day SMA ($) 2.2815
12-1 Month Momentum % -82.62
52-Week Range ($) 1.7117 - 17.39
Shares Outstanding (Mil) 47.69

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Finch Therapeutics Group Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More